List clinical trials by disease

Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

Searched for: Kidney Cancer. 21 results shown below.
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Principal Investigator: Robert Montgomery, MD

Study Number: 6932

Phase: NA



Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Complete title: ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy with Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

Principal Investigator: Ramesh Rengan

Study Number: 9712

Phase: II



Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Complete title: ADVL1622, Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1622

Phase: II



A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS

Principal Investigator: John Thompson, MD

Study Number: 20150061

Phase: I



Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

Principal Investigator: Andrew Coveler, MD

Study Number: 20150420

Phase: I



Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)
Complete title: A Phase 1A/1B Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

Principal Investigator: John Thompson, MD

Study Number: 20151981

Phase: I



A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Complete title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Principal Investigator: John Thompson, MD

Study Number: 20152183

Phase: II



Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Principal Investigator: Gabriela Chiorean

Study Number: 20152369

Phase: II



A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Complete title: A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Principal Investigator: Scott Tykodi, MD

Study Number: 20152576

Phase: III



Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Complete title: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: John Thompson, MD

Study Number: 20152783

Phase: I



A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Principal Investigator: Gabriela Chiorean

Study Number: 20160524

Phase: I



Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Principal Investigator: Scott Tykodi, MD

Study Number: 20160860

Phase: I/II



Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Principal Investigator: John Thompson, MD

Study Number: 20161740

Phase: I



Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Complete title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)

Principal Investigator: Scott Tykodi, MD

Study Number: 20161907

Phase: II



Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)
Complete title: A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162312

Phase: I/II



A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
Complete title: A Phase 1/2, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-214 and Anti-PD-L1 (Atezolizumab) or Anti-PD-1 (Nivolumab, Pembrolizumab) in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162818

Phase: I/II



A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Principal Investigator: Scott Tykodi, MD

Study Number: 20162874

Phase: II



A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Principal Investigator: Kit Wong

Study Number: 20171486

Phase: I



Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Complete title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Principal Investigator: Scott Tykodi, MD

Study Number: 20171511

Phase: III



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Erin Pinto

Study Number: SC-4008

Phase: II



Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Complete title: SC-4014 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors

Principal Investigator: Julie Park, MD

Study Number: SC-4014

Phase: I



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials